4//SEC Filing
Lister Troy 4
Accession 0000950170-25-003852
CIK 0001840574other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 9:00 AM ET
Size
7.8 KB
Accession
0000950170-25-003852
Insider Transaction Report
Form 4
Lister Troy
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-08+225,000→ 225,000 totalExercise: $6.01Exp: 2035-01-07→ Common Stock (225,000 underlying) - Award
Restricted Stock Units
2025-01-08+40,000→ 40,000 total→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F3]On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0002023489
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 9:00 AM ET
- Size
- 7.8 KB